Most notably, De Munter et al. designed a TCR-like nanobody CAR-T therapeutic with two tandem TCR-like nanobodies bispecific to HER2 and CD20 to activate T cells and kill tumor cells [13]. This evidence concerns the gene ERBB2 and neoplasm.